Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
recombinant interferon alfa · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| recombinant interferon alfa | BIOLOGICAL | - |
| fluorouracil | DRUG | - |
DISEASE CHARACTERISTICS: * Histologically proven carcinoid tumor with radiologically confirmed metastatic disease * Recurrence after surgery or radiotherapy allowed * Must meet at least 1 of the following conditions: * Symptomatic carcinoid syndrome not controlled * Other systemic symptoms (e....
Recombinant interferon alfa is an investigational biologic being studied for the treatment of gastrointestinal carcinoid tumors, a type of neuroendocrine tumor. It is being evaluated in combination with fluorouracil for patients with advanced metastatic carcinoid tumors. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Recombinant interferon alfa is being developed by Atlantic International Corp. (ticker: ATLN). The company is conducting clinical research on this investigational drug for the treatment of gastrointestinal carcinoid tumors. As a Phase 2 asset, it remains in clinical development and is not yet commercially available.
Recombinant interferon alfa is currently in Phase 2 clinical development. It is being studied in a completed Phase 2 trial for gastrointestinal carcinoid tumors. The drug is investigational and has not received FDA approval, meaning it is still being evaluated for safety and efficacy in clinical trials.
Recombinant interferon alfa has one completed clinical trial, NCT00002470, titled 'Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors.' This Phase 2 study enrolled patients with gastrointestinal carcinoid tumors and lung cancer in the United States. The trial was uncontrolled and did not use randomization or blinding.
Recombinant interferon alfa is a biologic agent that modulates the immune system's response to cancer cells. It is being studied in combination with fluorouracil for the treatment of gastrointestinal carcinoid tumors. The drug's mechanism involves enhancing the body's natural immune defenses against tumor cells, though specific molecular targets have not been detailed.